Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (RHINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03622593
Recruitment Status : Enrolling by invitation
First Posted : August 9, 2018
Last Update Posted : December 9, 2020
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

The global enrollment phase has closed, but participants are still being recruited only at sites in China.


Condition or disease Intervention/treatment Phase
Diabetic Macular Edema Drug: Aflibercept Drug: Faricimab Drug: Sham Procedure Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 951 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)
Actual Study Start Date : October 9, 2018
Actual Primary Completion Date : October 19, 2020
Estimated Study Completion Date : July 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: A: Faricimab Q8W Drug: Faricimab
Faricimab will be administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or as specified in the protocol in arm B.
Other Names:
  • RO6867461
  • RG7716

Drug: Sham Procedure
The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
Experimental: B: Faricimab As Specified in Protocol Drug: Faricimab
Faricimab will be administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or as specified in the protocol in arm B.
Other Names:
  • RO6867461
  • RG7716

Drug: Sham Procedure
The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
Active Comparator: C: Aflibercept Q8W Drug: Aflibercept
Aflibercept will be administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
Other Name: Eylea

Drug: Sham Procedure
The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) at 1 Year [ Time Frame: Baseline (Day 1) and 1 year ]
    As measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters.


Secondary Outcome Measures :
  1. Percentage of Participants with a ≥2-Step Diabetic Retinopathy Severity (DRS) Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) at 1 Year [ Time Frame: Baseline and 1 year ]
  2. Change From Baseline in BCVA Over Time [ Time Frame: From Baseline up to 2 years ]
  3. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline Over Time [ Time Frame: From Baseline up to 2 years ]
  4. Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline Over Time [ Time Frame: From Baseline up to 2 years ]
  5. Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline Over Time [ Time Frame: From Baseline up to 2 years ]
  6. Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline Over Time [ Time Frame: From Baseline up to 2 years ]
  7. Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline Over Time [ Time Frame: From Baseline up to 2 years ]
  8. Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline Over Time [ Time Frame: From Baseline up to 2 years ]
  9. Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline Over Time [ Time Frame: From Baseline up to 2 years ]
  10. Percentage of Participants Avoiding a Loss of >0 Letters in BCVA From Baseline Over Time [ Time Frame: From Baseline up to 2 years ]
  11. Percentage of Participants Gaining ≥15 Letters or Achieving BCVA of ≥84 Letters Over Time [ Time Frame: Up to 2 years ]
  12. Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time [ Time Frame: Up to 2 years ]
  13. Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time [ Time Frame: Up to 2 years ]
  14. Percentage of Participants with a ≥2-Step DRS Improvement From Baseline on the ETDRS DRSS Over Time [ Time Frame: From Baseline up to 2 years ]
  15. Percentage of Participants with a ≥3-Step DRS Improvement From Baseline on the ETDRS DRSS Over Time [ Time Frame: From Baseline up to 2 years ]
  16. Percentage of Participants Who Develop New Proliferative Diabetic Retinopathy Over Time [ Time Frame: Up to 2 years ]
  17. Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 1 Year [ Time Frame: 1 year ]
  18. Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 2 Years [ Time Frame: 2 years ]
  19. Change From Baseline in Central Subfield Thickness Over Time [ Time Frame: From Baseline up to 2 years ]
  20. Change From Baseline in Central Subfield Thickness at 1 Year [ Time Frame: Baseline and 1 year ]
  21. Percentage of Participants with Absence of DME Over Time [ Time Frame: Up to 2 years ]
  22. Percentage of Participants with Absence of Intraretinal Fluid Over Time [ Time Frame: Up to 2 years ]
  23. Percentage of Participants with Absence of Subretinal Fluid Over Time [ Time Frame: Up to 2 years ]
  24. Percentage of Participants with Absence of Intraretinal Fluid and Subretinal Fluid Over Time [ Time Frame: Up to 2 years ]
  25. Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time [ Time Frame: From Baseline up to 2 years ]
  26. Percentage of Participants with At Least One Ocular Adverse Event [ Time Frame: Up to 2 years ]
  27. Percentage of Participants with At Least One Non-Ocular Adverse Event [ Time Frame: Up to 2 years ]
  28. Plasma Concentration of Faricimab Over Time [ Time Frame: Pre-dose on Day 1; Weeks 4, 28, 52, 76, and 100; and at Early Termination Visit (up to 2 years) ]
  29. Percentage of Participants with Presence of Anti-Drug Antibodies [ Time Frame: Pre-dose on Day 1; Weeks 4, 28, 52, 76, and 100; and at Early Termination Visit (up to 2 years) ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
  • Hemoglobin A1c (HbA1c) of less than or equal to (≤)10% within 2 months prior to Day 1
  • Macular thickening secondary to diabetic macular edema (DME) involving the center of the fovea
  • Decreased visual acuity attributable primarily to DME
  • Ability and willingness to undertake all scheduled visits and assessments
  • For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 3 months after the final dose of study treatment

Exclusion Criteria:

  • Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1
  • Uncontrolled blood pressure, defined as a systolic value greater than (>)180 millimeters of mercury (mmHg) and/or a diastolic value >100 mmHg while a patient is at rest
  • Currently pregnant or breastfeeding, or intend to become pregnant during the study
  • Treatment with panretinal photocoagulation or macular laser within 3 months prior to Day 1 to the study eye
  • Any intraocular or periocular corticosteroid treatment within 6 months prior to Day 1 to the study eye
  • Prior administration of IVT faricimab in either eye
  • Active intraocular or periocular infection or active intraocular inflammation in the study eye
  • Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye
  • Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye
  • Other protocol-specified inclusion/exclusion criteria may apply
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03622593


Locations
Show Show 196 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03622593    
Other Study ID Numbers: GR40398
2017-005105-12 ( EudraCT Number )
First Posted: August 9, 2018    Key Record Dates
Last Update Posted: December 9, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).

For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Edema
Edema
Macular Degeneration
 Retinal Degeneration
Retinal Diseases
Eye Diseases